论文部分内容阅读
目的:研究护肝清脂片对非酒精性脂肪肝的药效情况。方法:大鼠按体重随机分为空白组、模型组、非诺贝特组(0.1g/kg)、护肝清脂片高(2.16g/kg)、中(1.08g/kg)、低剂量组(0.54g/kg)。采用高脂饲料造模,同时给予各组大鼠相应的药物连续10周。实验结束后,腹主动脉采血并处死所有大鼠,观察大鼠肝组织病理改变情况,并测定各组大鼠的血脂、肝指数、血糖、肝脏抗氧化能力等指标。结果:相较于模型组,护肝清脂片高、中剂量组大鼠的肝指数和MDA都明显下降;SOD、CAT、TAOC则明显升高。结论:护肝清脂片高(2.16g/kg)、中(1.08g/kg)剂量组能有效改善及预防非酒精性脂肪肝模型大鼠脂肪变性及炎症损伤,具有降低血脂水平、提高抗氧化能力等疗效。
Objective: To study the effect of Huganqingzhi tablet on non-alcoholic fatty liver. Methods: The rats were randomly divided into blank group, model group, fenofibrate group (0.1g / kg), Hugan Qingliang Tablet (2.16g / kg) Group (0.54 g / kg). Using high-fat diet modeling, while giving each group of rats corresponding drugs for 10 consecutive weeks. At the end of the experiment, blood was drawn from the abdominal aorta and sacrificed. All the rats were sacrificed and the pathological changes of the liver were observed. The indexes of blood lipids, liver index, blood glucose and liver antioxidant capacity were also determined. Results: Compared with the model group, the liver index and MDA of Huanghuangqinglipian high and middle dose groups were significantly decreased; while SOD, CAT and TAOC were significantly increased. Conclusion: Hugan Qinglian tablet (2.16g / kg) and medium dose (1.08g / kg) can effectively improve and prevent steatosis and inflammatory injury in nonalcoholic fatty liver disease rats. It has the effects of lowering blood lipid level, Oxidation and other effects.